相关实验视频

Updated: Jan 18, 2026

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

奇洛斯塔增加了附带重塑,并降低了缺血性中风的严重程度

Hua Zhang¹, Ming-Chieh Ding², Gabriel Gong¹

¹Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism

|January 16, 2026

概括

奇洛斯塔是一种FDA批准的药物,通过促进血管改造,可显著增强中风后的附带血液流动. 这种重新定位提供了一个有前途的治疗策略,以改善中风患者的治疗结果.

科学领域:

神经科学是一个神经科学.
心血管研究研究心血管研究
药理学药理学是指药理学的学科.

背景情况:

确定治疗方法来增加中风后的附带血液流量至关重要.
奇洛斯塔是一种FDA批准的药物,目前用于预防复发性中风和暂时性缺血性发作.

研究的目的:

调查重定向西洛斯塔的潜力,以诱导附带重塑和增加急性缺血性中风后的血液流动.
在小鼠中风模型中评估西洛斯塔在改善功能结果和减少心脏病发作量方面的疗效.

主要方法:

具有不同基线附带状态的小鼠在中脑动脉 (MCA) 堵塞后2小时开始接受临床剂量的西洛斯塔.
评估了附带增长,相对附带流量,心脏病发作量和功能结果.
还评估了与实验药物的联合治疗.

主要成果:

在具有良好的基线抵押品的小鼠中,西洛斯塔显著促进了抵押品的增长,并增加了31%的相对抵押品流.
在具有不良附带的小鼠中,西洛斯塔将附带流量增加了275%,显著降低了心脏病发作量并改善了功能.
组合疗法导致附带流量额外增加了261%.
在老年小鼠和患有糖尿病的小鼠中观察到益处.

结论:

奇洛斯塔有效地促进侧边重塑,并增强中风后的血液流动,提供了一个新的治疗途径.
该药物在改善功能结果和减少大脑损伤方面表现出有效性,即使在具有挑战性的条件下,如基线担保不良,晚年和糖尿病.
这些发现支持进一步的临床前和临床研究,用于治疗中风的西洛斯塔.

关键词:

担保翻新改造担保翻新改造担保改造急性缺血性中风是急性缺血性中风.动脉的产生是动脉的产生.大脑循环大脑循环基洛斯塔佐尔 (cilostazol) 是一种可靠的药物.

更多相关视频

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

相关概念视频

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...